Your browser doesn't support javascript.
loading
Rapid relaxation of pandemic restrictions after vaccine rollout favors growth of SARS-CoV-2 variants: A model-based analysis.
Van Egeren, Debra; Stoddard, Madison; Novokhodko, Alexander; Rogers, Michael S; Joseph-McCarthy, Diane; Zetter, Bruce; Chakravarty, Arijit.
Afiliación
  • Van Egeren D; Department of Systems Biology, Harvard Medical School, Boston, MA, United States of America.
  • Stoddard M; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Novokhodko A; Stem Cell Program, Boston Children's Hospital, Boston, MA, United States of America.
  • Rogers MS; Fractal Therapeutics, Cambridge, MA, United States of America.
  • Joseph-McCarthy D; Department of Mechanical Engineering, University of Washington, Seattle, WA, United States of America.
  • Zetter B; Vascular Biology Program, Boston Children's Hospital, Boston, MA, United States of America.
  • Chakravarty A; Department of Biomedical Engineering, Boston University, Boston, MA, United States of America.
PLoS One ; 16(11): e0258997, 2021.
Article en En | MEDLINE | ID: mdl-34818335
ABSTRACT
The development and deployment of several SARS-CoV-2 vaccines in a little over a year is an unprecedented achievement of modern medicine. The high levels of efficacy against transmission for some of these vaccines makes it feasible to use them to suppress SARS-CoV-2 altogether in regions with high vaccine acceptance. However, viral variants with reduced susceptibility to vaccinal and natural immunity threaten the utility of vaccines, particularly in scenarios where a return to pre-pandemic conditions occurs before the suppression of SARS-CoV-2 transmission. In this work we model the situation in the United States in May-June 2021, to demonstrate how pre-existing variants of SARS-CoV-2 may cause a rebound wave of COVID-19 in a matter of months under a certain set of conditions. A high burden of morbidity (and likely mortality) remains possible, even if the vaccines are partially effective against new variants and widely accepted. Our modeling suggests that variants that are already present within the population may be capable of quickly defeating the vaccines as a public health intervention, a serious potential limitation for strategies that emphasize rapid reopening before achieving control of SARS-CoV-2.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Modelos Estadísticos / Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 / Mutación Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Modelos Estadísticos / Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 / Mutación Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos